Cancer Immunotherapy Market Worth 115.4 Billion USD by 2026

The global Cancer Immunotherapy market size is anticipated to around USD 115.4 billion by 2026, this market is anticipated to grow with 10.6% CAGR during the forecast time period.

North America dominated the global cancer immunotherapy market in the year 2018. The region has experienced the potential growth owing to the presence of cancer immunotherapy companies such as Novartis AG, Bayer AG, Amgen Inc., Astrazeneca, and Bristol-Myers Squibb, ELI Lilly and Companyamong others. The presence of a large customer base along with favorable reimbursement policies is additionally accelerating the regional market growth. Moreover, favorable medicare policies and growing number of hospitals and clinic centers are expected to enhance the market growth in the global cancer immunotherapy market in future.

According to American Cancer Society, in 2017, around 15.8 million cancer cases are diagnosed and it is expected to witness the growth of cancer cases with 16.5 million in 2018. Growing prevalence of such diseases further expected to raise the demand for cancer immunotherapy in North America. The Europe region is expected to exhibit a second-largest share in the cancer immunotherapy market. Stringent government regulations regarding hospital devices and rapid industrialization, technological advancement in therapy, growing number of treatmentin countries, such as Germany, the UK, France, Spain, and Italy, are expected to enhance the market growth in the global cancer immunotherapy market during the forecast.

Asia-Pacific region is expected to exhibit highest CAGR in the cancer immunotherapy market. The rapid growth in the urbanization, huge patient population, growing healthcare industry in developing countries, and liberalization of foreign direct investment in the medical sector is the major driving factor for the region in the global market. Moreover, the rising geriatric population and growing awareness regarding treatment options increases its dominance in the global cancer immunotherapy market in future.

Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1700

Growing demand for cancer immunotherapy in various end user applications growing awareness about cancer treatment across the globe and multi-functionality of cancer immunotherapy are the main drivers for the market growth of the global cancer immunotherapy market over the forecast period. Furthermore, rising investment in research and development of cancer treatment and supportive government initiatives further grows the demand for cancer immunotherapy over the forecast the period. Moreover, technological advancement and increase in the number of applications, and availability of advanced healthcare facilities in developing countries are expected to enhance the market size. This also expected to open investment opportunities in the global market for the manufacturers in the coming years.

However, high treatment costs of cancer immunotherapy, low purchasing power of consumers, risk associated with the therapy are expected to hamper the growth of the global cancer immunotherapy market during the forecast period.

Monoclonal antibodies segment have dominated the product segment in the year 2018 and the segment is projected to maintain its dominance over the forecast period from 2019 to 2026. Growing prevalence of blood cancer, epiretinal membrane and diabetic retinopathy and escalating demand for monoclonal antibodies further expected to drive the demand for the segment. The manufacturers Novartis AG, Bayer AG, ELI Lilly and Company, and Janssen Global Services, LLC are the mainly investing in the development ofmonoclonal antibodies, which expected the lead the market in the coming years.

Related Reports

Hepatitis B Vaccine Market - The global market size is expected to reach around US$ 2,136.7 Mn by 2026 and growing at a CAGR of around 5.8% from forecast period 2019 to 2026.
Vaccines Market -The global market is expected to grow at a CAGR of around 6.4% from forecast period 2019 to 2026 and to reach the market value of around US$ 55.2 billion by 2026.
Meningococcal Vaccines Market - The global market value is estimated to hit USD 9.37 billion by 2026 and expected to grow at a CAGR of 12.3% over period 2019 to 2026.

Hospital segment dominated the cancer immunotherapy market on the basis of end user in the year 2018. The major factors that are driving the growth of this segment are availability of high-tech equipment and technologies in hospitals and growing number of hospitals across the globe. In hospitals there are variety of treatment and wide number of diagnostics options. This will result in a shorter duration of hospitalization and overall physician observation hours. This expected to enhance the dominance of the hospital segment in the global market over the forecast period.

Some of the leading competitors are Janssen Global Services, LLC, Merck, Pfizer, F. Hoffmann-La Roche Ltd, Amgen, Inc., Novartis AG, Bayer AG, Amgen Inc., Astrazeneca, and Bristol-Myers Squibb, ELI Lilly and Company.

Some of the key observations regarding cancer immunotherapyindustry include:

In July 2019, Abbott Medical Optics Inc. announced partnership agreement with Johnson & Johnson, a provider of advanced software solutions for life science R&D. The partnership increases the development of cancer immunotherapyproducts and increases the efficiency of strain development processes.
In October 2018, Carl Zeiss Meditec AG signed acquisition agreement with IanTech. The acquisition focuses on providing technological solutions for cancer treatment.
In November 2018, Novartis AG received approval from European commission for luxturna, a gene therapy to treat patients with a vision loss. The approval enhances the brand identity of the company and enhances its customer base.

Market Segmentation

Market By Product Type

Monoclonal Antibodies
Vaccines
Checkpoint Inhibitors
Cell Therapies
Immunomodulators

Market By Application

Breast Cancer
Lung Cancer
Multiple Myeloma
Colorectal Cancer
Head & Neck Cancer
Prostate Cancer
Melanoma
Others

Market By End-user

Hospitals
Clinics & Others

Key Questions Answered in the Report

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

- What is the overall structure of the market?

- What was the historical value and what is the forecasted value of the market?

- What are the key product level trends in the market?

- What are the market level trends in the market?

- Which of the market players are leading and what are their key differential strategies to retain their stronghold?

- Which are the most lucrative regions in the market space?

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1700

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Cancer Immunotherapy
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cancer Immunotherapy Market By Product Type
1.2.2.1. Global Cancer Immunotherapy Market Revenue and Growth Rate Comparison By Product Type (2015-2026)
1.2.2.2. Global Cancer Immunotherapy Market Revenue Share By Product Type in 2018
1.2.2.3. Monoclonal Antibodies
1.2.2.4. Vaccines
1.2.2.5. Checkpoint Inhibitors
1.2.2.6. Cell Therapies
1.2.2.7. Immunomodulators
1.2.3. Cancer Immunotherapy Market By Application
1.2.3.1. Global Cancer Immunotherapy Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.1.1. Breast Cancer
1.2.3.1.2. Lung Cancer
1.2.3.1.3. Multiple Myeloma
1.2.3.1.4. Colorectal Cancer
1.2.3.1.5. Head & Neck Cancer
1.2.3.1.6. Prostate Cancer
1.2.3.1.7. Melanoma
1.2.3.1.8. Others
1.2.4. Cancer Immunotherapy Market By End-user
1.2.4.1. Global Cancer Immunotherapy Market Revenue and Growth Rate Comparison By End-user (2015-2026)
1.2.4.2. Hospitals
1.2.4.3. Clinics & Others
1.2.5. Cancer Immunotherapy Market By Geography
1.2.5.1. Global Cancer Immunotherapy Market Revenue and Growth Rate Comparison By Geography (2015-2026)
1.2.5.2. North America Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)
1.2.5.3. Europe Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)
1.2.5.4. Asia-Pacific Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)
1.2.5.5. Latin America Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)
1.2.5.6. Middle East and Africa (MEA) Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Cancer Immunotherapy Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Cancer Immunotherapy Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Cancer Immunotherapy Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Cancer Immunotherapy Major Manufacturers in 2018

CHAPTER 4. CANCER IMMUNOTHERAPY MARKET BY PRODUCT TYPE
4.1. Global Cancer Immunotherapy RevenueBy Product Type
4.2. Monoclonal Antibodies
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Checkpoint Inhibitors
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Cell Therapies
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Immunomodulators
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. CANCER IMMUNOTHERAPY MARKET BY APPLICATION
5.1. Global Cancer Immunotherapy RevenueBy Application
5.2. Breast Cancer
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Lung Cancer
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Multiple Myeloma
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Colorectal Cancer
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Head & Neck Cancer
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Prostate Cancer
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Melanoma
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Others
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. CANCER IMMUNOTHERAPY MARKET BY END-USER
6.1. Global Cancer Immunotherapy Revenue By End-user
6.2. Hospitals
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Clinics & Others
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY
7.1. North America Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Cancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S.Cancer Immunotherapy Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY
8.1. Europe Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Cancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFICCANCER IMMUNOTHERAPY MARKET BY COUNTRY
9.1. Asia-Pacific Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-PacificCancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY
10.1. Latin America Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Cancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY
11.1. Middle East & Africa Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East & Africa Cancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.5. Rest of Middle East & Africa
11.5.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE
12.1. Novartis AG
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Type Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Bayer AG
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Type Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Amgen Inc.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Type Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Astrazeneca
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Type Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Bristol-Myers Squibb
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Type Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. ELI Lilly and Company
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Type Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Janssen Global Services, LLC
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Type Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Merck
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Type Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Pfizer
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Type Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. F. Hoffmann-La Roche Ltd
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Type Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Others
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Type Portfolio
12.11.5. Key Developments
12.11.6. Strategies

CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/1700

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1-407-915-4157 OR +1-408-900-9135

About Us

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. Among the industries served include aerospace and defense, information and communication technology (ICT), semiconductor and electronics, healthcare and pharmaceuticals, chemicals, advanced materials, banking, finance services and insurance (BFSI), and others.

Our collective industry experience of over 100 years has helped us to offer appropriate market information and our global reach and regional connects ensures appropriate insights into regional markets to guarantee apt delivery of information.

Our regional market intelligence helps our clients to identify potential opportunities and develop growth strategies across regions and countries. Our services are geared towards offering best market research to our clients.

Contact Us: Mr. Frank Wilson
Acumen Research and Consulting
17890, Castleton St #218
Rowland Heights, CA 91748 United States
Tel: +1-407-915-4157 OR +1-408-900-9135
Email: sales@acumenresearchandconsulting.com Website: https://www.acumenresearchandconsulting.com